Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

NCT04551053 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04551053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04551053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Terminated
Start date
May 26, 2021
Completion date
August 21, 2024
Enrollment
177 (actual)
Sites
177

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, post essential thrombocythemia myelofibrosis, post polycythemia vera myelofibrosis, primary myelofibrosis